Therapeutic Solutions Launches VasoSome Vascular Inc. to Commercialize Aortic Aneurysm Treatment

May 1, 2023—Therapeutic Solutions International announced formation of a new spin-off company, VasoSome Vascular Inc., which is focused on treating aortic aneurysms using stem cell–derived exosomes. The results demonstrated that administration of stem cell-derived exosomes suppress growth of aortic aneurysms in an animal model.

VasoSome Vascular is currently performing investigational new drug–enabling studies and hopes to file with the FDA by the end of 2023 to initiate a phase I/II clinical trial. The company’s exosome therapy is patent pending.

James Veltmeyer, MD, who is Chief Medical Officer of Therapeutic Solutions International, commented in the press release, “Aortic aneurysms affect an estimated at 1.3% to 8.9% of men and 1.0% to 2.2% of women. Of these, a significant portion are ineligible for surgical or endovascular approaches. The basis of VasoSome Vascular is to utilize stem cell exosomes to stabilize and possibly even reverse growth of aortic aneurysms.”

Dr. Veltmeyer continued, “Based on our clinical experiences using JadiCells and other stem cell products, I am confident as a physician that the field of aortic aneurysms is a relatively wide-open space for application of regenerative medicine. I am excited to assist the new company in advancing its initial milestones.”

Timothy Dixon, President and CEO of Therapeutic Solutions International, added, “We are excited to be commercializing the utilization of these nanoparticles called ‘exosomes’ in overcoming limitations of existing stem cell therapies to diffuse the ‘living time bomb’ known as aortic aneurysms. By leveraging the potency of our regenerative medicine base, we are grateful to be able to generate so many new companies across diverse areas of biology in order to advance patient treatments and augment shareholder value to the highest extent possible.”